Gujarat Terce Laboratories Ltd (GUJTERC) is currently trading at 34.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Gujarat Terce Laboratories Limited is an Ahmedabad‑headquartered pharmaceutical manufacturer focused primarily on oral solid dosages, including tablets and capsules, serving domestic Indian markets. The company operates a manufacturing facility at Chhatral with installed capacity of 270 million tablets and 108 million capsules per annum, and markets branded generics across Paediatrics, Gynaecology, Orthopaedics and physician segments. FY26 financials show revenue of INR 4,747 lacs, a modest decline of 5% versus FY25, while reported PAT turned positive at INR 220 lacs compared with a loss in the prior year. EBITDA for the year was INR 363 lacs with a 7.66% margin, reflecting improvement in earnings quality, stronger net worth and positive operating cash generation versus the previous year. The fourth quarter was challenging: Q4 revenue declined eight percent to INR 1,139.93 lacs and EBITDA fell sharply to INR 36.93 lacs with margin compressing to 3.24%. Despite quarter‑level margin pressure, Q4 delivered a positive reported PAT of INR 10.1 lacs versus a substantial loss in Q4 FY25, indicating that structural improvements and financial discipline supported bottom‑line resilience. Commercial footprint includes presence across 13 states and 224 districts, supported by 385 stockists, 150 medical representatives and relationships with over 32,700 medical practitioners and 30,074 chemists. This distribution infrastructure and focused field force enable deep penetration in northern, western and central India, facilitating rapid product availability across urban, semi‑urban and rural channels and supporting brand reach for core therapeutic areas. Management emphasises strengthening brand equity, enhancing field productivity and maintaining financial discipline, citing net worth improvement of over fifty percent during FY26. The company intends to prioritise profitability before scale, using improved liquidity and lower finance costs to support selective brand investments and operational efficiencies rather than aggressive expansion, creating a more stable platform for future growth.

Over the past 52 weeks, Gujarat Terce Laboratories Ltd has traded between a low of ₹29.00 and a high of ₹51.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Gujarat Terce Laboratories Ltd has a market capitalization of approximately 26.59. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Gujarat Terce Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 12.78 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 26.59 Cr, Gujarat Terce Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Gujarat Terce Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Gujarat Terce Laboratories Ltd is 12.78. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.